公开(公告)号：US20230271936A1

公开(公告)日：2023-08-31

申请号：US18040598

申请日：2021-08-09

申请人： Abbisko Therapeutics Co., Ltd

发明人： Fei Yang ,  Shuqun Yang ,  Hongping Yu ,  Zhui Chen ,  Yaochang Xu

IPC分类号： C07D401/12 ,  C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D401/14 ,  C07D405/14

CPC分类号： C07D401/12 ,  C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D401/14 ,  C07D405/14

摘要： An EGFR inhibitor having the structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use of same as an EGFR inhibitor, and a use of same in preparing a drug for treating and/or preventing a cancer, a tumor, or a metastatic disease at least partially related to an EGFR exon 20 insertion, deletion, or other mutation, and in particular a use in preparing a drug for treating and/or preventing a hyperproliferative disease and an induced cell death disorder. Each substituent of formula (I) has the same definition as in the description.

公开(公告)号：US11149021B2

公开(公告)日：2021-10-19

申请号：US16610970

申请日：2018-05-22

申请人： Abbisko Therapeutics Co., Ltd.

发明人： Baowei Zhao ,  Mingming Zhang ,  Hongping Yu ,  Shuqun Yang ,  Zhui Chen ,  Yaochang Xu

IPC分类号： C07D401/14 ,  A61P35/00 ,  C07D413/14

摘要： An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.